KEYNOTE-010, a phase III randomized clinical trial comparing pembrolizumab to docetaxel, found in its subgroup analysis of EGFR-mutated NSCLC patients that pembrolizumab did not improve OS compared with docetaxel. Here, EGFR is linked to non-small cell lung carcinoma.